Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation

DC FieldValueLanguage
dc.contributor.authorZendaoui, Adnane-
dc.contributor.authorLachance, Dominic-
dc.contributor.authorRoussel, Élise-
dc.contributor.authorCouët, Jacques-
dc.contributor.authorArsenault, Marie-
dc.date.accessioned2017-11-14T18:23:51Z-
dc.date.available2017-11-14T18:23:51Z-
dc.date.issued2011-03-15-
dc.identifier.issn1941-3289fr
dc.identifier.urihttp://hdl.handle.net/20.500.11794/15842-
dc.description.abstractBackground — Aortic regurgitation (AR) is a chronic disease for which there is currently no approved medical treatment. We previously reported in an animal model that β-blockade with metoprolol exerted beneficial effects on left ventricular remodeling and survival. Despite the recent publication of promising human data, β-blockade in chronic AR remains controversial. More data are needed to support this potentially new treatment strategy. We hypothesized that carvedilol might be another safe treatment option in chronic AR, considering its combined β-blocking and α-blocking effects and proven efficacy in patients with established heart failure. Methods and Results — The effects of a 6-month treatment with carvedilol 30 mg/kg/d orally were evaluated in adult Wistar rats with severe AR. Sham-operated and untreated AR animals were used as controls. Carvedilol treatment resulted in less left ventricular hypertrophy and dilatation. Ejection fraction was improved and filling pressures were reduced by carvedilol. β1-Receptor expression was also improved as well as myocardial capillary density. Those beneficial effects were noted despite the presence of drug-induced bradycardia. Conclusions — Carvedilol exerted protective effects against volume-overload cardiomyopathy in this model of aortic valve regurgitation with preserved ejection fraction. These results suggest a protective class effect of β-blockers. Combined with the recent publication of promising human data, our findings support the need to carefully design a prospective study in humans to evaluate the effects of β-blockers in chronic aortic valve regurgitation.fr
dc.languageengfr
dc.publisherLippincott Williams & Wilkinsfr
dc.subjectAortic valve regurgitationfr
dc.subjectVolume overloadfr
dc.subjectLeft ventricular hypertrophyfr
dc.subjectBeta blockersfr
dc.titleUsefulness of carvedilol in the treatment of chronic aortic valve regurgitationfr
dc.title.alternativeCarvedilol treatment for aortic valve regurgitationfr
dc.typeCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherchefr
dcterms.bibliographicCitationCirculation. Heart failure, Vol. 4 (2), 207–213 (2011)fr
dc.identifier.doi10.1161/CIRCHEARTFAILURE.110.958512fr
dc.identifier.pubmed21216836fr
dc.subject.rvmCarvédilolfr
dc.subject.rvmCœur -- Ventricule gauche -- Hypertrophiefr
dc.subject.rvmCœur -- Valvules -- Maladiesfr
dc.subject.rvmBêtabloquantsfr
rioxxterms.versionAccepted Manuscriptfr
rioxxterms.version_of_recordhttps://doi.org/10.1161/CIRCHEARTFAILURE.110.958512fr
rioxxterms.project.funder_nameCanadian Institutes of Health Researchfr
rioxxterms.project.funder_nameQuebec Heart Institute Corporationfr
bul.rights.periodeEmbargo6 moisfr
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
Description SizeFormat 
4.pdf515.43 kBAdobe PDFThumbnail
View/Open
All documents in CorpusUL are protected by Copyright Act of Canada.